{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:49:13Z","timestamp":1793922553541,"version":"4.8.0"},"reference-count":81,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"\n Importance<\/jats:title>\n Mortality among people with opioid dependence is higher than that of the general population. Opioid agonist treatment (OAT) is an effective treatment for opioid dependence; however, there has not yet been a systematic review on the relationship between OAT and specific causes of mortality.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the association of time receiving OAT with mortality.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n The Embase, MEDLINE, and PsycINFO databases were searched through February 18, 2020, including clinical trial registries and previous Cochrane reviews.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n All observational studies that collected data on all-cause or cause-specific mortality among people with opioid dependence while receiving and not receiving OAT were included. Randomized clinical trials (RCTs) were also included.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Data on study, participant, and treatment characteristics were extracted; person-years, all-cause mortality, and cause-specific mortality were calculated. Crude mortality rates and rate ratios (RRs) were pooled using random-effects meta-analyses.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Overall all-cause and cause-specific mortality both by setting and by participant characteristics. Methadone and buprenorphine OAT were evaluated specifically.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Fifteen RCTs including 3852 participants and 36 primary cohort studies including 749\u202f634 participants were analyzed. Among the cohort studies, the rate of all-cause mortality during OAT was more than half of the rate seen during time out of OAT (RR,\u20090.47; 95% CI, 0.42-0.53). This association was consistent regardless of patient sex, age, geographic location, HIV status, and hepatitis C virus status and whether drugs were taken through injection. Associations were not different for methadone (RR,\u20090.47; 95% CI, 0.41-0.54) vs buprenorphine (RR,\u20090.34; 95% CI, 0.26-0.45). There was lower risk of suicide (RR, 0.48; 95% CI, 0.37-0.61), cancer (RR, 0.72; 95% CI, 0.54-0.98), drug-related (RR, 0.41; 95% CI, 0.33-0.52), alcohol-related (RR, 0.59; 95% CI, 0.49-0.72), and cardiovascular-related (RR, 0.69; 95% CI, 0.60-0.79) mortality during OAT. In the first 4 weeks of methadone treatment, rates of all-cause mortality and drug-related poisoning were more than double the rates during the remainder of OAT (RR, 2.81; 95% CI, 1.55-5.09) but not for buprenorphine (RR, 0.58; 95% CI, 0.18-1.85). All-cause mortality was 6 times higher in the 4 weeks after OAT cessation (RR, 6.01; 95% CI, 4.32-8.36), remaining double the rate for the remainder of time not receiving OAT (RR, 1.81; 95% CI, 1.50-2.18). Opioid agonist treatment was associated with a lower risk of mortality during incarceration (RR, 0.06; 95% CI, 0.01-0.46) and after release from incarceration (RR, 0.09; 95% CI, 0.02-0.56).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This systematic review and meta-analysis found that OAT was associated with lower rates of mortality. However, access to OAT remains limited, and coverage of OAT remains low. Work to improve access globally may have important population-level benefits.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2021.0976","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T11:07:16Z","timestamp":1622632036000},"page":"979","source":"Crossref","is-referenced-by-count":603,"title":["Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence"],"prefix":"10.1001","volume":"78","author":[{"suffix":"Jr","given":"Thomas","family":"Santo","sequence":"first","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brodie","family":"Clark","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Hickman","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Campbell","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia"},{"name":"University of the Sunshine Coast, Sunshine Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Sordo","sequence":"additional","affiliation":[{"name":"Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain"},{"name":"Department of Preventive Medicine and Public Health, Faculty of Medicine, Complutense University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Chen","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia"},{"name":"Clinical Research Unit for Anxiety and Depression, St Vincent's Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy Thi","family":"Tran","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrianna","family":"Bharat","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prianka","family":"Padmanathan","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grainne","family":"Cousins","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dupouy","sequence":"additional","affiliation":[{"name":"University Department of General Medicine, University of Toulouse, Faculty of Medicine, Toulouse, France"},{"name":"Inserm UMR1027, University of Toulouse III, Faculty of Medicine, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Kelty","sequence":"additional","affiliation":[{"name":"The School of Population & Global Health, The University of Western Australia, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Muga","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Germans Trias i Pujol-IGTP University Hospital, Autonomous University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Min","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimondo","family":"Pavarin","sequence":"additional","affiliation":[{"name":"Epidemiological Monitoring Center on Addiction, Azienda Unit\u00e0 Sanitaria Locale Bologna, Mental Health Dipartimento Salute Mentale \u2013 Dipendenze Patologiche, Bologna, Italy"},{"name":"Italian Society on Addiction, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farrell","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[{"name":"National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"yoi210027r1","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/add.v114.9","article-title":"Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.","volume":"114","author":"Irvine","year":"2019","journal-title":"Addiction"},{"issue":"10208","key":"yoi210027r2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: harms to populations, interventions, and future action.","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet"},{"issue":"10259","key":"yoi210027r3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0140-6736(20)32113-9","article-title":"The opioid crisis and the 2020 US election: crossroads for a national epidemic.","volume":"396","author":"Wen","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"yoi210027r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037679","article-title":"Trends in the diagnosis of diseases of despair in the United States, 2009-2018: a retrospective cohort study.","volume":"10","author":"Brignone","year":"2020","journal-title":"BMJ Open"},{"issue":"5","key":"yoi210027r5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamapsychiatry.2019.4170","article-title":"All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis.","volume":"77","author":"Larney","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"yoi210027r7","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"10062","key":"yoi210027r8","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","article-title":"Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.","volume":"388","author":"Stevens","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"yoi210027r9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"15","key":"yoi210027r10","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"yoi210027r12","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"yoi210027r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004666","article-title":"Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study.","volume":"4","author":"Larney","year":"2014","journal-title":"BMJ Open"},{"key":"yoi210027r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.05.011","article-title":"A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.","volume":"142","author":"Gordon","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"yoi210027r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.11.021","article-title":"A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification.","volume":"94","author":"Gruber","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"yoi210027r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2009.03.002","article-title":"A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease.","volume":"37","author":"Kinlock","year":"2009","journal-title":"J Subst Abuse Treat"},{"key":"yoi210027r22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"yoi210027r23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"key":"yoi210027r24","doi-asserted-by":"publisher","journal-title":"Lancet","DOI":"10.1016\/S0140-6736(14)62338-2"},{"key":"yoi210027r25","doi-asserted-by":"publisher","journal-title":"Ann Intern Med","DOI":"10.7326\/0003-4819-119-1-199307010-00004"},{"key":"yoi210027r26","doi-asserted-by":"publisher","journal-title":"Am J Public Health","DOI":"10.2105\/AJPH.81.9.1185"},{"key":"yoi210027r27","doi-asserted-by":"publisher","journal-title":"Lancet","DOI":"10.1016\/S0140-6736(03)12600-1"},{"key":"yoi210027r28","doi-asserted-by":"publisher","journal-title":"Addiction","DOI":"10.1046\/j.1360-0443.2002.00090.x"},{"key":"yoi210027r29","doi-asserted-by":"publisher","journal-title":"Lancet","DOI":"10.1016\/S0140-6736(08)60954-X"},{"key":"yoi210027r30","doi-asserted-by":"publisher","journal-title":"JAMA Psychiatry","DOI":"10.1001\/jamapsychiatry.2017.3206"},{"key":"yoi210027r31","doi-asserted-by":"publisher","journal-title":"Lancet","DOI":"10.1016\/S0140-6736(79)91550-2"},{"key":"yoi210027r32","doi-asserted-by":"publisher","journal-title":"Drug Alcohol Depend","DOI":"10.1016\/0376-8716(81)90096-X"},{"key":"yoi210027r33","doi-asserted-by":"publisher","journal-title":"J Acquir Immune Defic Syndr","DOI":"10.1097\/QAI.0000000000000510"},{"key":"yoi210027r34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","article-title":"Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment\u2014a nation-wide register-based open cohort study.","volume":"174","author":"Abrahamsson","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"yoi210027r35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0269881116675508","article-title":"Benzodiazepine maintenance in opiate substitution treatment: good or bad? a retrospective primary care case-note review.","volume":"31","author":"Bakker","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"1","key":"yoi210027r36","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12913-019-4382-9","article-title":"From restrictive to more liberal: variations in mortality among patients in opioid maintenance treatment over a 12-year period.","volume":"19","author":"Bukten","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"yoi210027r37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1046\/j.1360-0443.2002.00179.x","article-title":"An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam.","volume":"97","author":"Buster","year":"2002","journal-title":"Addiction"},{"issue":"3","key":"yoi210027r38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jsat.2011.05.001","article-title":"Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study.","volume":"41","author":"Cousins","year":"2011","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"yoi210027r39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/add.v111.1","article-title":"Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study.","volume":"111","author":"Cousins","year":"2016","journal-title":"Addiction"},{"issue":"12","key":"yoi210027r40","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1111\/add.2007.102.issue-12","article-title":"Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study.","volume":"102","author":"Davoli","year":"2007","journal-title":"Addiction"},{"issue":"4","key":"yoi210027r41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1370\/afm.2098","article-title":"Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study.","volume":"15","author":"Dupouy","year":"2017","journal-title":"Ann Fam Med"},{"key":"yoi210027r42","doi-asserted-by":"publisher","author":"Durand","year":"2020","DOI":"10.1111\/add.v115.10"},{"issue":"3","key":"yoi210027r43","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/add.2007.102.issue-3","article-title":"Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings.","volume":"102","author":"Fugelstad","year":"2007","journal-title":"Addiction"},{"issue":"3","key":"yoi210027r44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/acp.1990.82.issue-3","article-title":"Mortality in heroin addiction: impact of methadone treatment.","volume":"82","author":"Gr\u00f6nbladh","year":"1990","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"yoi210027r45","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/add.v113.8","article-title":"The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.","volume":"113","author":"Hickman","year":"2018","journal-title":"Addiction"},{"issue":"5","key":"yoi210027r46","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2105\/AJPH.91.5.774","article-title":"The impact of harm-reduction-based methadone treatment on mortality among heroin users.","volume":"91","author":"Langendam","year":"2001","journal-title":"Am J Public Health"},{"issue":"8","key":"yoi210027r47","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/add.v112.8","article-title":"Does exposure to opioid substitution treatment in prison reduce the risk of death after release? a national prospective observational study in England.","volume":"112","author":"Marsden","year":"2017","journal-title":"Addiction"},{"issue":"6","key":"yoi210027r48","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.drugpo.2013.09.001","article-title":"Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine.","volume":"24","author":"Morozova","year":"2013","journal-title":"Int J Drug Policy"},{"key":"yoi210027r49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/1471-2334-14-504","article-title":"Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study.","volume":"14","author":"Muga","year":"2014","journal-title":"BMC Infect Dis"},{"key":"yoi210027r50","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jsat.2017.02.009","article-title":"Mortality trends among heroin users treated between 1975 and 2013 in Northern Italy: results of a longitudinal study.","volume":"77","author":"Pavarin","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"yoi210027r51","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/add.v111.2","article-title":"Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England.","volume":"111","author":"Pierce","year":"2016","journal-title":"Addiction"},{"issue":"9","key":"yoi210027r52","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1055\/s-2002-33758","article-title":"Does maintenance treatment reduce the mortality rate of opioid addicts?.","volume":"70","author":"Scherbaum","year":"2002","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"6765","key":"yoi210027r53","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/bmj.301.6765.1362","article-title":"Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone.","volume":"301","author":"Weber","year":"1990","journal-title":"BMJ"},{"issue":"1-2","key":"yoi210027r54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"yoi210027r55","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/add.2004.99.issue-4","article-title":"Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).","volume":"99","author":"Digiusto","year":"2004","journal-title":"Addiction"},{"issue":"6","key":"yoi210027r56","first-page":"443","article-title":"Opioid-dependent error processing.","volume":"7","author":"Fellows-Smith","year":"2011","journal-title":"J Opioid Manag"},{"issue":"3","key":"yoi210027r57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/00952990.2018.1545131","article-title":"A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.","volume":"45","author":"Kelty","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"10","key":"yoi210027r58","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","article-title":"Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study.","volume":"2","author":"Kimber","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"yoi210027r59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/10550880903435988","article-title":"Favorable mortality profile of naltrexone implants for opiate addiction.","volume":"29","author":"Reece","year":"2010","journal-title":"J Addict Dis"},{"key":"yoi210027r61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.drugalcdep.2015.05.033","article-title":"Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan.","volume":"153","author":"Chang","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"yoi210027r62","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1111\/add.2011.106.issue-8","article-title":"Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan.","volume":"106","author":"Huang","year":"2011","journal-title":"Addiction"},{"issue":"3","key":"yoi210027r63","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jsat.2012.08.003","article-title":"Factors associated with mortality among heroin users after seeking treatment with methadone: a population-based cohort study in Taiwan.","volume":"44","author":"Huang","year":"2013","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"yoi210027r64","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/infdis\/jit163","article-title":"Factors associated with mortality of HIV-positive clients receiving methadone maintenance treatment in China.","volume":"208","author":"Liu","year":"2013","journal-title":"J Infect Dis"},{"issue":"5-6","key":"yoi210027r65","first-page":"444","article-title":"Causes and rates of death among methadone maintenance patients before and after the onset of the HIV\/AIDS epidemic.","volume":"67","author":"Appel","year":"2000","journal-title":"Mt Sinai J Med"},{"issue":"6","key":"yoi210027r66","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1111\/add.12863","article-title":"Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10.","volume":"110","author":"Evans","year":"2015","journal-title":"Addiction"},{"issue":"2","key":"yoi210027r67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/oxfordjournals.aje.a112012","article-title":"An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction.","volume":"100","author":"Gearing","year":"1974","journal-title":"Am J Epidemiol"},{"issue":"3","key":"yoi210027r68","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"yoi210027r69","doi-asserted-by":"publisher","first-page":"m772","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"key":"yoi210027r70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jsat.2016.12.005","article-title":"Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013.","volume":"74","author":"Ledberg","year":"2017","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"yoi210027r71","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/add.12536","article-title":"The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study.","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction"},{"issue":"3","key":"yoi210027r72","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/ije\/dyh124","article-title":"Commentary: the hormone replacement\u2013coronary heart disease conundrum: is this the death of observational epidemiology?","volume":"33","author":"Lawlor","year":"2004","journal-title":"Int J Epidemiol"},{"key":"yoi210027r73","doi-asserted-by":"publisher","first-page":"m2511","DOI":"10.1136\/bmj.m2511","article-title":"Health effects of vitamin and mineral supplements.","volume":"369","author":"Zhang","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"yoi210027r75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: a systematic review.","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"yoi210027r76","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/aje\/kwp186","article-title":"Proportional hazards frailty models for recurrent methadone maintenance treatment.","volume":"170","author":"Nosyk","year":"2009","journal-title":"Am J Epidemiol"},{"key":"yoi210027r77","doi-asserted-by":"publisher","first-page":"c3172","DOI":"10.1136\/bmj.c3172","article-title":"Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment.","volume":"341","author":"Kimber","year":"2010","journal-title":"BMJ"},{"issue":"12","key":"yoi210027r78","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/add.13073","article-title":"A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence.","volume":"110","author":"Gisev","year":"2015","journal-title":"Addiction"},{"issue":"7779","key":"yoi210027r80","doi-asserted-by":"publisher","first-page":"c5475","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database.","volume":"341","author":"Cornish","year":"2010","journal-title":"BMJ"},{"key":"yoi210027r81","doi-asserted-by":"publisher","author":"Zhang","year":"2015","DOI":"10.1371\/journal.pone.0139942"},{"key":"yoi210027r13","author":"Sterne","year":"2019"},{"key":"yoi210027r15","volume-title":"Stata Statistical Software: Release 16","author":"StataCorp","year":"2019"},{"key":"yoi210027r16","author":"Harris","year":"2008"},{"key":"yoi210027r17","author":"Harbord","year":"2009"},{"key":"yoi210027r60","author":"Bazazi","year":"2018"},{"key":"yoi210027r74","doi-asserted-by":"crossref","DOI":"10.1002\/9780470870709","volume-title":"Competing Risks: A Practical Perspective","author":"Pintilie","year":"2006"},{"key":"yoi210027r6","unstructured":"World Health Organization. WHO Model list of essential medicines. Accessed February 15, 2020. https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/essential-medicines-lists"},{"key":"yoi210027r11","unstructured":"Examining the effect of opioid agonist treatment on all-cause and cause-specific mortality. PROSPERO identifier: CRD42020171949. Updated April 28, 2020. Accessed April 21, 2021. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=171949"},{"key":"yoi210027r14","unstructured":"Randall? D, Roxburgh? A, Gibson? A, Degenhardt? L. Mortality among people who use illicit drugs: a toolkit for classifying major causes of death. Accessed January 23, 2010. https:\/\/ndarc.med.unsw.edu.au\/sites\/default\/files\/ndarc\/resources\/Randall%20et%20al%20Classifying%20causes%20of%20death%202009%20corrected.pdf"},{"key":"yoi210027r79","unstructured":"Department of Health. Drug misuse and dependence. Accessed April 15, 2020. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/673978\/clinical_guidelines_2017.pdf"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2780655\/jamapsychiatry_santo_2021_oi_210027_1689697193.11148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T11:23:21Z","timestamp":1689765801000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2780655"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}